Hvsen Biotech: In the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line

Hvsen Biotech stated on the investor interaction platform that the pet medicine sector is one of the company's key development directions. The company is adjusting resource allocation and increasing investment in the research and development of pet medicines and market channel construction. It has established an independent and specialized pet medicine R&D team, and in the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line. The company's pet medicines mainly involve sub-sectors such as pet deworming, antipyretic and analgesic, dermatological medications, internal medicine diseases, and functional health products